RT Journal Article
SR Electronic
T1 Impact of SARS-CoV-2 on the microbiota of pregnant women and their infants
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.11.01.22281810
DO 10.1101/2022.11.01.22281810
A1 Leftwich, Heidi K.
A1 Vargas-Robles, Daniela
A1 Rojas-Correa, Mayra
A1 Yap, Yan Rou
A1 Bhattarai, Shakti
A1 Ward, Doyle V.
A1 Fujimori, Gavin
A1 Forconi, Catherine S.
A1 Yeboah, Tracy
A1 Carter, Acara
A1 Kastrinakis, Alyssa
A1 Asirwatham, Alison M.
A1 Bucci, Vanni
A1 Moormann, Ann M.
A1 Maldonado-Contreras, Ana
YR 2022
UL http://medrxiv.org/content/early/2022/11/02/2022.11.01.22281810.abstract
AB The microbiome inherited at birth exerts marked effects on immune programming with long-term health consequences. Here, we demonstrated that the gut, vaginal, and oral microbial diversity of pregnant women with SARS-CoV-2 infection is reduced, and women with early infections exhibit a different vaginal microbiota composition compared to healthy controls at the time of delivery. Accordingly, infants born to pregnant women with early SARS-CoV-2 infection exhibit a unique oral microbiota dominated by Streptococcus species. Together, we demonstrated that SARS-CoV-2 infections during pregnancy, particularly early infections, are associated with lasting changes in the microbiome of pregnant women compromising the initial microbial seed of their infant. Our results highlight the importance of further exploring the impact of SARS-CoV-2 on the infant’s microbiome-dependent immune programming.One Sentence Summary Pregnant patients with SARS-CoV-2 infection early in pregnancy and with active infection exhibit an altered vaginal and oral microbiota that is passed on to infants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementHL, AMM, and AMC received funding to execute this study from the COVID-19/Pandemic Research Fund at UMass Chan Medical School. HL is also funded by the Worcester Foundation Grant. Funding sources for AMM, GF, and CF were also provided by MassCPR Evergrande Award. AMM was supported through the National Institutes of Health, NCI Serological Sciences Network (U01 CA261276). AMC is funded by The Leona M. and Harry B. Helmsley Charitable Trust.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board at the University of Massachusetts Chan Medical School.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequencing data are available in a public, open-access repository: the NCBI database, BioProject ID: PRJNA871082. Additional de-identified clinical metadata are available on reasonable request. https://dataview.ncbi.nlm.nih.gov/object/PRJNA871082?reviewer=9jjclf6enqcubg06bf88d65pmb